1University of Kragujevac, Faculty of Medical Sciences, Department of Ophthalmology, Kragujevac, Serbia; 2Department of Ophthalmology, Kragujevac Clinical Center, Kragujevac, Serbia.
Acta Clin Croat. 2021 Jun;60(2):231-236. doi: 10.20471/acc.2021.60.02.08.
The aim of the study was to assess the impact of primary argon laser trabeculoplasty (ALT) on intraocular pressure (IOP) lowering and quality of life improvement in patients with pseudoexfoliative glaucoma. Sixty patients with newly diagnosed pseudoexfoliative glaucoma who underwent primary ALT (group 2) or medication therapy (group 1) were followed-up. The effect of ALT on IOP reduction, dry eye development and number of antiglaucoma drugs used was examined. Patients were examined at the beginning of the study and then after 6, 12, and 18 months. A statistically significant difference between IOP values was observed throughout the 18-month follow-up, with the highest significance recorded 6 months after ALT (p=0.009). Twelve months after the start of the study, the TBUT value was 6.0±0.8 s in group 1 and 8.4±0.7 s in group 2. In group 2, the value of Schirmer test was constantly above 10 millimeters. The number of antiglaucoma medications used in group 1 was statistically significantly higher as compared to group 2 throughout the 18-month study period. ALT was found to be better choice for temporary regulation of IOP in patients with pseudoexfoliative glaucoma.
本研究旨在评估原发性氩激光小梁成形术(ALT)对原发性开角型青光眼患者眼压降低和生活质量改善的影响。60 例新诊断为原发性开角型青光眼的患者接受了原发性 ALT(第 2 组)或药物治疗(第 1 组)。研究中检查了 ALT 对眼压降低、干眼症发展和抗青光眼药物使用数量的影响。患者在研究开始时和 6、12 和 18 个月后接受检查。在 18 个月的随访期间,观察到眼压值存在统计学显著差异,ALT 后 6 个月记录到最高显著性(p=0.009)。研究开始后 12 个月,第 1 组的 TBUT 值为 6.0±0.8 秒,第 2 组为 8.4±0.7 秒。在第 2 组中,Schirmer 测试值始终高于 10 毫米。第 1 组在整个 18 个月的研究期间,抗青光眼药物的使用数量明显高于第 2 组。ALT 是治疗原发性开角型青光眼患者眼压的较好选择。